NCT01636206 - Safety Study of Lifitegrast to Treat Dry Eye | Biotech Hunter

Enrollment

332

Participants

Timeline

Start Date

October 16, 2012

Primary Completion Date

March 3, 2014

Study Completion Date

March 3, 2014

Conditions

Dry Eye Disease

Interventions

DRUG

Lifitegrast

Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: \~1 year

DRUG

Placebo

Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: \~1 year

Trial Locations (23)

11570

SONATA Investigational Site, Rockville Centre

14618

SONATA Investigational Site, Rochester

18902

SONATA Investigational Site, Doylestown

27262

SONATA Investigational Site, High Point

28210

SONATA Investigational Site, Charlotte

29464

SONATA Investigational Site, Mt. Pleasant

30076

SONATA Investigational Site, Roswell

33426

SONATA Investigational Site, Boynton Beach

37411

SONATA Investigational Site, Chattanooga

40509

SONATA Investigational Site, Lexington

41017

SONATA Investigational Site, Edgewood

44115

SONATA Investigational Site, Cleveland

55082

SONATA Investigational Site, Stillwater

60169

SONATA Investigational Site, Hoffman Estates

77204

SONATA Investigational Site, Houston

80134

SONATA Investigational Site, Parker

90640

SONATA Investigational Site, Montebello

90701

SONATA Investigational Site, Artesia

92545

SONATA Investigational Site, Hemet

92653

SONATA Investigational Site, Laguna Hills

93534

SONATA Investigational Site, Lancaster

08534

SONATA Investigational Site, Pennington

07424

SONATA Investigational Site, Woodland Park